1499 / 1835
13-034 Cohort 4 Study Design
Brentuximab (1.2 mg/m
2
)+ AVD x 2 cycles
PET-CT-2
PET-CT-4
Biopsy
Bx-
Bx+
No RT
Off study
Brentuximab (1.2 mg/m
2
)+ AVD x 2 cycles
Eligiblity:
•
Histologically confirmed cHL
•
Stage I or II
•
Bulky mediastinal mass (≥7cm in
MTD or MCD)